2BBBullish & Bearish
Bicycle Therapeutics (BCYC) trades on NASDAQ. It operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Its current 2BB score is 50 out of 100.
Bicycle Therapeutics’s current 2BB score is 50 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 55 | Moderate |
| Momentum | 80 | Strongly Improving |
| Financial strength | 24 | Weak |
| Quality | 90 | Very Strong |
| Risk | 41 | Moderate |
| CEO | Kevin Lee |
| Founded | 2009 |
| Employees | 288 |
| 52-week range | $3.74 – $9.16 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-10-28 | — | -0.4771 | — | $1.53M |
| 2026-08-06 | — | -0.5753 | — | $4.87M |